Phosphorus Containing Patents (Class 514/51)
  • Publication number: 20130165401
    Abstract: Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
    Type: Application
    Filed: January 2, 2013
    Publication date: June 27, 2013
    Applicant: GILEAD PHARMASSET LLC
    Inventor: GILEAD PHARMASSET LLC
  • Publication number: 20130164260
    Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: November 16, 2012
    Publication date: June 27, 2013
    Applicant: Gilead Sciences, Inc.
    Inventor: Gilead Sciences, Inc.
  • Patent number: 8461124
    Abstract: Conformationally locked 2?,4?-carbocylic nucleosides with improved thermal and nuclease stability are disclosed. Oligonucleotides incorporating the locked nucleosides, and methods of treating disease states, are also disclosed.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: June 11, 2013
    Inventor: Jyoti Chattopadhyaya
  • Publication number: 20130143835
    Abstract: The invention provides compounds of the formula: which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.
    Type: Application
    Filed: December 4, 2012
    Publication date: June 6, 2013
    Applicant: MEDIVIR AB
    Inventor: Medivir AB
  • Publication number: 20130137654
    Abstract: Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
    Type: Application
    Filed: January 10, 2013
    Publication date: May 30, 2013
    Applicant: GILEAD PHARMASSET LLC
    Inventor: GILEAD PHARMASSET LLC
  • Patent number: 8445458
    Abstract: A composition comprising (a) one or more ?-3 fatty acids selected from DHA, DPA and EPA, (b) uridine or its equivalent, and (c) a methyl donor, useful in the treatment of a person having characteristics of a prodromal dementia patient. The characteristics include e.g. a level of more than 350 ng Total-tau per liter cerebrospinal fluid (CSF), and a weight ratio of abeta-42/Phospho-tau-181 of less than 6.5 in CSF.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: May 21, 2013
    Assignee: N. V. Nutricia
    Inventors: Robert Johan Joseph Hageman, Patrick Joseph Gerardus Hendrikus Kamphuis, Ladislaus Maria Broersen
  • Patent number: 8445457
    Abstract: A pharmaceutical solution suitable for oral administration comprising ?-L-thymidine/2?-deoxy-L-thymidine (telbivudine), a pharmaceutically suitable solvent system, one or more taste-enhancing/masking agents, a preservative system, and a buffer system suitable to allow both drug stability and preservation.
    Type: Grant
    Filed: July 10, 2008
    Date of Patent: May 21, 2013
    Assignee: Novartis AG
    Inventor: Nabila Sekkat
  • Publication number: 20130109647
    Abstract: Disclosed herein is a method of treating a subject infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period. Also disclosed herein is a composition useful for the treatment of hepatitis C virus infection, said composition comprising an effective amount of GS-7977 and an effective amount of ribavirin.
    Type: Application
    Filed: October 26, 2012
    Publication date: May 2, 2013
    Applicant: GILEAD PHARMASSET LLC
    Inventor: Gilead Pharmasset LLC
  • Publication number: 20130102526
    Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
    Type: Application
    Filed: October 19, 2012
    Publication date: April 25, 2013
    Applicant: ABBVIE INC.
    Inventor: ABBVIE INC.
  • Patent number: 8415322
    Abstract: The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2?R)-2?-deoxy-2?-fluoro-2?-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: April 9, 2013
    Assignee: Gilead Pharmasset LLC
    Inventor: Jeremy Clark
  • Patent number: 8410075
    Abstract: Disclosed are Mannich base N-oxides of drugs containing acidic N—H groups. Pharmaceutical compositions comprising a therapeutically effective amount of Mannich base N-oxides, or a N-oxide rearrangement product, pharmaceutically acceptable salt or prodrug thereof, are also disclosed. Further, disclosed are methods of using the compounds, alone or in combination with one or more other active agents or treatments.
    Type: Grant
    Filed: September 21, 2009
    Date of Patent: April 2, 2013
    Assignee: Cascade Prodrug Inc.
    Inventors: John F. W. Keana, Paul Westberg, John Curd, Alshad S. Lalani
  • Publication number: 20130078217
    Abstract: The present invention relates to 2?-chloroacetylenyl-substituted nucleoside derivatives of the general formula (I): As well as pharmaceutical compositions comprising such compounds and methods to treat or prevent an HIV infection, HBV infection, HCV infection or abnormal cellular proliferation, comprising administering said compounds or compositions. In addition, the present invention includes processes for the preparation of such compounds, and the related ?-D and ?-L-nucleoside derivatives.
    Type: Application
    Filed: September 21, 2012
    Publication date: March 28, 2013
    Inventors: Guoqiang Wang, In Jong Kim, Yat Sun Or
  • Patent number: 8404651
    Abstract: The present invention provides compositions methods for treating susceptible viral infections, especially hepatitis C viral (HCV) infections as well as co infections of HCV with other viruses such as HBV and/or HIV. In one embodiment, the present invention provides compositions having the formula (I) and their use in treating viral infections: or a pharmaceutically acceptable salt, ester, stereoisomer, tautomers, solvate, prodrug, or combination thereof.
    Type: Grant
    Filed: October 4, 2010
    Date of Patent: March 26, 2013
    Assignee: Spring Bank Pharmaceuticals, Inc.
    Inventors: Radhakrishnan P. Iyer, Seetharamaiyer Padmanabhan
  • Patent number: 8399429
    Abstract: Compounds of the formula I: including any possible stereoisomers thereof, wherein: R1 is hydrogen or halo; R4 is a monophosphate, diphosphate or triphosphate ester; or R4 is a group of formula R7 is optionally substituted phenyl; naphthyl; indolyl or N—C1-C6alkyloxycarbonyl-indolyl; R8 is hydrogen, C1-C6alkyl, benzyl; R8? is hydrogen, C1-C6alkyl, benzyl; or R8 and R8? together with the carbon atom to which they are attached form C3-C7cycloalkyl; R9 is C1-C10alkyl, benzyl, or optionally substituted phenyl; or a pharmaceutically acceptable salt or solvate thereof. pharmaceutical formulations and the use of compounds I as HCV inhibitors.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: March 19, 2013
    Assignees: Janssen Products, LP, Medivir AB
    Inventors: Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Steven Maurice Paula Van Hoof, Leen Anna Maria Vandekerckhove, Koen Vandyck
  • Patent number: 8394355
    Abstract: The present invention relates to methods for determining whether blood flow is restricted in a blood vessel of an individual suspected of compromised blood flow in the vessel, the method comprising the steps of delivering UTP, a derivative thereof, or a salt thereof to the vessel, assessing blood flow quantitatively in the vessel by obtaining a value that correlates to blood flow in said vessel, comparing the obtained value with a reference value, and determining whether the individual has compromised blood flow based on the results of the comparison. The invention also provides for methods of diagnosing atherosclerotic and ischemic heart diseases using UTP, a derivative thereof, or a salt thereof, as well as methods for inducing maximal hyperemia for diagnostic purposes.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: March 12, 2013
    Assignee: P2 science Aps
    Inventor: Jaya Brigitte Rosenmeier
  • Publication number: 20130053338
    Abstract: Pharmaceutical compositions containing P2X purinergic agonists, e.g. P2X3 agonists, for increasing insulin secretion in a subject, methods of use, and methods of screening for related compounds and agents.
    Type: Application
    Filed: March 21, 2011
    Publication date: February 28, 2013
    Inventors: Per-Olof Berggren, Alejandro Caicedo, Caroline M. Jacques-Silva
  • Publication number: 20130045949
    Abstract: Described herein are compounds that may be selectively activated to produce active anti-cancer agents in tumor cells. Also disclosed are pharmaceutical compositions comprising the compounds, and methods of treating cancer using the compounds.
    Type: Application
    Filed: July 1, 2012
    Publication date: February 21, 2013
    Applicant: UWM RESEARCH FOUNDATION, INC.
    Inventors: Xiaohua Peng, Yunyan Kuang, Sheng Cao, Wenbing Chen, Yibin Wang
  • Publication number: 20130029929
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Application
    Filed: September 11, 2012
    Publication date: January 31, 2013
    Applicant: GILEAD PHARMASSET LLC
    Inventors: Michael Joseph Sofia, Jinfa Du, Peiyuan Wang, Dhanapalan Nagarathnam
  • Patent number: 8361988
    Abstract: The present invention comprises compounds useful as antiviral or antitumor agents. The compounds comprise nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moeities with quaternary centers at the 3? position. The nucleotide analogues can be used to inhibit cancer or viruses. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting diseases or conditions associated with cancers and viruses. Thus, the present invention also comprising pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit viruses or tumors and treat, prevent, or inhibit the foregoing diseases.
    Type: Grant
    Filed: January 17, 2008
    Date of Patent: January 29, 2013
    Assignee: Institut de Recherches Cliniques de Montreal
    Inventor: Yvan Guindon
  • Patent number: 8362078
    Abstract: The present invention relates to the use of polyunsaturated fatty acids and one or more components which have a beneficial effect on total methionine metabolism selected from the group consisting of vitamin B12 and precursors thereof, vitamin B6 and derivatives thereof, folic acid, zinc and magnesium, in the manufacture of a preparation for improving the action of receptors. This preparation is advantageously applied in patients suffering from Parkinson's disease, Huntington's chorea, epilepsy, schizophrenia, paranoia, depression, sleep disorders, impaired memory function, psychoses, dementia and ADHD.
    Type: Grant
    Filed: December 1, 2008
    Date of Patent: January 29, 2013
    Assignee: N.V. Nutricia
    Inventors: Amanda Johanne Kiliaan, Robert Johan Joseph Hageman
  • Publication number: 20130018012
    Abstract: The invention pertains to the use of a lipid fraction for the support of brain function. The lipid fraction comprises the medium-chain fatty acids at least 4 g hexanoic acid and/or at least 5 g octanoic acid, at least 1 g eicosapentaenoic acid, and in addition more than 0.4 g ?-linolenic acid per 100 g fatty acids of the lipid fraction.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 17, 2013
    Inventors: Robert Johan Joseph Hageman, Eline Marleen van der Beek, Martine Groenendijk, Patrick Joseph Gerardus Hendrikus Kamphuis
  • Publication number: 20130018011
    Abstract: The application provides methods for treatment or prophylaxis of dengue virus mediated diseases with compounds of Formula I wherein R1, R2a, R2b, R3, R4, R5 R6, R8a, R9 and R10 are as defined herein. The application further discloses methods for treatment or prophylaxis of dengue virus mediated diseases with pharmaceutical compositions comprising compounds of Formula I.
    Type: Application
    Filed: June 5, 2012
    Publication date: January 17, 2013
    Inventors: Hassan Javanbakht, Klaus G. Klumpp, Suping Ren, Zhuming Zhang
  • Publication number: 20130017171
    Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
    Type: Application
    Filed: September 20, 2012
    Publication date: January 17, 2013
    Applicants: UNIVERSITA DEGLI STUDI DI CAGLIARI, IDENIX PHARMACEUTICALS, INC.
    Inventors: Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari
  • Publication number: 20130012469
    Abstract: The invention pertains to a liquid composition for preventing and/or treating memory decline and/or cognitive dysfunction, Alzheimer's, Parkinson's and/or dementia, said composition comprising: (i) at least 50 mg nucleoside and/or nucleotide per 100 ml; (ii) between 0.2 and 10 grams protein per 100 ml; (iii) between 0.05 and 3 wt. % of thickener, based on total weight of the composition. The thickener is preferably selected from the group consisting of cellulose, xanthan gum, gellan gum, alginate, guar gum, locust bean gum, gum karaya, gum tragacanth, carrageenan, and mixtures thereof. The composition preferably has a loss factor tan ? between 0.1 and 100, as measured at any strain in the range of 1-100% at 0.1 Hz and 20° C. It is particularly found that a thickener selected from the group consisting of gellan gum, xanthan gum and cellulose greatly reduces sedimentation.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Inventors: Esther Jacqueline DE KORT, Robert Johan Joseph Hageman, Martine Groenendijk, Patrick Joseph Gerardus Hendrikus Kamphuis
  • Patent number: 8343937
    Abstract: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
    Type: Grant
    Filed: September 25, 2006
    Date of Patent: January 1, 2013
    Assignees: Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari
    Inventors: Jean-Pierre Sommadossi, Paulo LaColla
  • Patent number: 8334270
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Grant
    Filed: May 3, 2011
    Date of Patent: December 18, 2012
    Assignee: Gilead Pharmasset LLC
    Inventors: Michael Joseph Sofia, Jinfa Du, Peiyuan Wang, Dhanapalan Nagarathnam
  • Publication number: 20120301464
    Abstract: Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.
    Type: Application
    Filed: August 1, 2012
    Publication date: November 29, 2012
    Applicant: INCYTE CORPORATION
    Inventors: Paul A. Friedman, Jordan S. Fridman, Monica E. Luchi, William V. Williams
  • Publication number: 20120295862
    Abstract: Embodiments are disclosed herein that involve C5-functionalized nucleic acids, which can be used for detecting a target in a nucleic acid. Particular embodiments disclose methods for making these compounds, wherein the compounds can be formed by coupling of an intermediate with a linker. Certain embodiments disclose the use of these compounds for detecting single nucleotide polymorphisms, and for increasing the thermal affinity of nucleic acid complements as compared to unmodified nucleic acid complements. In addition, the disclosed compounds can decrease enzymatic degradation of nucleic acids.
    Type: Application
    Filed: March 9, 2012
    Publication date: November 22, 2012
    Inventors: Patrick J. Hrdlicka, Pawan Kumar, Michael E. Østergaard
  • Patent number: 8314064
    Abstract: The present invention provides methods of stimulating or enhancing production of a cellular membrane, improving a cognitive function or a neurological function, treating or ameliorating a decline in a cognitive function or a neurological function, increasing cytidine levels, or treating a neurological disorder in a subject, comprising administering a uridine, a uridine precursor, or a derivative or metabolite thereof to the subject. The invention also provides methods of improving neural function, comprising contacting the neuron with a uridine, a uridine precursor, or a derivative or metabolite thereof.
    Type: Grant
    Filed: October 26, 2004
    Date of Patent: November 20, 2012
    Assignee: Massachusetts Institute of Technology
    Inventors: Carol Watkins, Richard J. Wurtman
  • Publication number: 20120277178
    Abstract: Compositions and methods of treatment or prophylaxis of fragile-X associated disorders are provided, as well as methods of screening compounds and kits to screen a library of compounds.
    Type: Application
    Filed: April 27, 2012
    Publication date: November 1, 2012
    Applicant: EMORY UNIVERSITY
    Inventors: Peng JIN, Abrar QURASHI
  • Patent number: 8299038
    Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: October 30, 2012
    Assignees: Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari
    Inventors: Jean-Pierre Sommadossi, Paulo LaColla
  • Publication number: 20120270830
    Abstract: Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including theanine and one or more exogenous nucleotides. The nutritional compositions can be specifically used to treat functional bowel disorders, including inflammatory bowel syndrome.
    Type: Application
    Filed: August 23, 2010
    Publication date: October 25, 2012
    Applicant: NESTEC S.A.
    Inventors: Norman Alan Greenberg, Peter Geoffrey McLean, Magali Faure
  • Publication number: 20120269725
    Abstract: Method of using androgen receptor and/or butyrylcholinesterase targeted radiolabeled compounds, e.g., cycloSalingenyl pyrimidine nucleoside monophosphates, for the treatment and diagnosis of cancer.
    Type: Application
    Filed: December 23, 2010
    Publication date: October 25, 2012
    Inventors: Janine Baranowska-Kortylewicz, Zbigniew P. Kortylewicz
  • Publication number: 20120263678
    Abstract: Provided are compounds of Formula I: nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.
    Type: Application
    Filed: April 13, 2012
    Publication date: October 18, 2012
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Aesop Cho, Choung U. Kim, Thorsten A. Kirschberg, Michael R. Mish, Neil Squires
  • Publication number: 20120258928
    Abstract: Cyclic phosphate of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof, represented by the following structure:
    Type: Application
    Filed: April 5, 2012
    Publication date: October 11, 2012
    Applicant: GILEAD PHARMASSET LLC
    Inventors: JINFA DU, DHANAPALAN NAGARATHNAM, GANAPATI REDDY PAMULAPATI, BRUCE S. ROSS, MICHAEL JOSEPH SOFIA
  • Patent number: 8283336
    Abstract: The invention pertains to a composition comprising (i) uridine in nucleobase, nucleoside and/or nucleotide form; (ii) docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA); and (iii) a tocopherol and/or an equivalent thereof, wherein said composition has: a) a weight of 200-3000 mg per unit dose; b) an energy content of less than 50 kcal per unit dose; and/or c) a volume between 0.1 and 10 ml per unit dose. The invention also pertains to the use of such composition in reducing abeta plaque burden and neurodegeneration, in the treatment of diseases related with imparted nerve functioning, in particular dementia, Alzheimer's disease and memory disorders.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: October 9, 2012
    Assignee: N. V. Nutricia
    Inventors: Martine Groenendijk, Robert Johan Joseph Hageman, Patrick Joseph Gerardus Hendrikus Kamphuis, Erwin Peke Meijer
  • Publication number: 20120237480
    Abstract: The present invention relates to 2?-allene-substituted nucleoside derivatives of the general formula (I): As well as pharmaceutical compositions comprising such compounds and methods to treat or prevent an HIV infection, HBV infection, HCV infection or abnormal cellular proliferation, comprising administering said compounds or compositions. In addition, the present invention includes processes for the preparation of such compounds, and the related ?-D and ?-L-nucleoside derivatives.
    Type: Application
    Filed: March 16, 2012
    Publication date: September 20, 2012
    Inventors: YAT SUN OR, Jun Ma, Guoqiang Wang, In Jong Kim, Jiang Long, Yao-Ling Qiu
  • Publication number: 20120225839
    Abstract: Compounds of formula I: including any possible stereoisomers thereof, wherein: R1 is hydrogen, —C(?O)R6 or —C(?O)CHR7—NH2; R2 is hydrogen; or C1-C6alkyl or phenyl, either of which is optionally substituted with 1, 2 or 3 substituents each independently selected from halo, C1-C6alkyl, C2-C6-alkenyl and C1-C6alkoxy, hydroxy or amino, or R2 is naphtyl; or R2 is indolyl, R3 is hydrogen, C1-C6alkyl, benzyl; R4 is hydrogen, C1-C6alkyl, benzyl; or R3 and R4 together with the carbon atom to which they are attached form C3-C7cycloalkyl; R5 is C1-C10alkyl, C3-C7-cycloalkyl, benzyl, or phenyl, any of which being optionally substituted with 1, 2 or 3 substituents each independently selected from hydroxy, C1-C6alkoxy, amino, mono- and diC1-C6alkylamino; R6 is C1-C6 alkyl; R7 is C1-C6 alkyl; R8 is hydrogen or halogen; or a pharmaceutically acceptable salt or solvate thereof are useful in the prophylaxis or treatment of HCV infections.
    Type: Application
    Filed: September 29, 2010
    Publication date: September 6, 2012
    Inventors: Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Michael Pelcman, Bengt Christian Sund, Horst Jurgen Wahling, Pedro Manuel Passos Pinho, Anna Winqvist, Karl Magnus Nilsson
  • Patent number: 8258116
    Abstract: The present invention relates to therapeutic combinations comprising a protease inhibitor and a polymerase inhibitor for the treatment of HCV. The present invention also relates to therapeutic combinations comprising VX-950 and a polymerase inhibitor. Also within the scope of the invention are methods using the therapeutic combinations of the present invention for treating HCV infection or alleviating one or more symptoms thereof in a patient. The present invention also provides kits comprising the combinations of the present invention.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: September 4, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Ann Kwong, Nagraj Mani, Yi Zhou, Chao Lin
  • Patent number: 8242087
    Abstract: This invention relates to novel phosphate-modified nucleosides, and methods for producing them, being useful for the prevention or treatment of a viral infection in a mammal, and for preparing oligonucleotides by DNA/RNA polymerase-dependent amplification, e.g. PCR.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: August 14, 2012
    Assignee: K.U.Leuven Research & Development
    Inventors: Olga Adelfinskaya, Piet Herdewijn
  • Publication number: 20120189597
    Abstract: Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including one or more exogenous nucleotides.
    Type: Application
    Filed: August 9, 2010
    Publication date: July 26, 2012
    Applicant: NESTEC S.A.
    Inventors: Norman Alan Greenberg, Douglas Richard Bolster
  • Publication number: 20120190620
    Abstract: The present invention discloses methods to identify targets, pathways and molecules regulating purinosomes and their uses for treating pathophysiological disorders associated with purinosomes. Disclosed are methods related to both label-free cellular assays and fluorescence imaging to confirm the regulatory roles of various targets and molecules in purinosome dynamics. Disclosed are methods to classify molecules and the uses of these molecules for different indications. Specifically, the purinosome-disrupting molecules can be used for improved prevention and treatment of cancer development.
    Type: Application
    Filed: July 18, 2011
    Publication date: July 26, 2012
    Inventors: Stephen Benkovic, Ye Fang, Songon An, Florence Verrier
  • Publication number: 20120184503
    Abstract: Disclosed are nutritional compositions including human milk oligosaccharides and nucleotides that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
    Type: Application
    Filed: December 22, 2011
    Publication date: July 19, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Rachael Buck, Debra L. Thomas, Joseph P. Schaller
  • Publication number: 20120165286
    Abstract: Disclosed herein are cyclic nucleotide analogs, methods of synthesizing cyclic nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with cyclic nucleotide analogs.
    Type: Application
    Filed: December 20, 2011
    Publication date: June 28, 2012
    Applicant: ALIOS BIOPHARMA, INC.
    Inventors: Leonid Beigelman, David Bernard Smith, Jerome Deval, Vivek Kumar Rajwanshi
  • Patent number: 8207143
    Abstract: The present invention relates to the use of the compound according to formula (I), below for the treatment of tumors, cancer and hyperproliferative diseases, among other conditions or disease states: Where X is H or F; R1 and R2 are independently H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate or a phosphodiester group, a (A) or (B) group; Where Nu is a radical of a biologically active compound such as an anticancer, antiviral or antihyperproliferative compound such that an amino group or hydroxyl group from said biologically active agent forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety; each R8 is independently H, or a C1-C20 alkyl or ether group, preferably a C1-C12 alkyl group; k is 0-12, preferably, 0-2; and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: June 26, 2012
    Assignee: Yale University
    Inventor: Yung-chi Cheng
  • Patent number: 8193165
    Abstract: The present invention relates to novel compounds according to the general formulas I, II, III, IV or V: wherein B is nucleoside base according to the structure: and the remaining variables as defined in the specification, and pharmaceutical compositions comprising the compounds. The compounds are useful interalia as anti-viral agents in viral therapy.
    Type: Grant
    Filed: August 17, 2009
    Date of Patent: June 5, 2012
    Assignee: Yale University
    Inventors: Yung-chi Cheng, Hiromichi Tanaka, Masanori Baba
  • Patent number: 8193338
    Abstract: A di(pyrimidine nucleoside 5?-)polyphosphate is synthesized by converting a pyrimidine nucleoside 5?-triphosphate into a pyrimidine nucleoside 5?-cyclic triphosphate by use of a condensing agent, and subsequently reacting the pyrimidine nucleoside 5?-cyclic triphosphate with a pyrimidine nucleotide in the presence of a salt of a metal selected from among magnesium, manganese, and iron. Through the method of the invention, a di(pyrimidine nucleoside 5?-)polyphosphate can be synthesized from an unprotected pyrimidine nucleoside 5?-phosphate serving as a starting material at a synthesis yield of 50% or higher. Therefore, the method of the invention is suitable for large-scale synthesis of a di(pyrimidine nucleoside 5?-)polyphosphate.
    Type: Grant
    Filed: July 25, 2007
    Date of Patent: June 5, 2012
    Assignee: Yamasa Corporation
    Inventors: Satoru Kogo, Kohei Yamada, Yuko Iwai, Kazuomi Osawa, Hiroyuki Hayakawa
  • Publication number: 20120122810
    Abstract: Disclosed are polycyclic polyether compounds of formula I and pharmaceutical compositions comprising such compounds. wherein R, OR1, and R2 are as defined herein. Also disclosed are methods of regulating mucus clearance in a cell, and methods of treating decreased mucus clearance or mucociliary dysfunction.
    Type: Application
    Filed: January 23, 2012
    Publication date: May 17, 2012
    Inventors: Daniel G. Baden, William M. Abraham, Andrea J. Bourdelais, Sophie Michelliza
  • Patent number: 8173620
    Abstract: The disclosure encompasses caged compounds such as caged nucleoside phosphoesters (caged nucleotides). In an embodiment, the caged nucleotides include compounds corresponding to those described by formula (I) that may be activated by two-photon excitation, and methods of synthesis of such compounds. 8-Bromo-7-hydroxyquinoline-caged ATP was synthesized and examined for its photochemistry as a biologically useful, temporally and spatially controlled ATP-releasing reagent. The combination of two-photon excitation hydrolysis and activation of caged ATP enables methods for finely focusing ATP activation at the sub-cellular level or to a greater depth of activation, thereby providing improved resolution of ATP-dependent processes at the cellular level.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: May 8, 2012
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Timothy M. Dore, Yue Zhu, Khalilah G. Reddie, James D. Lauderdale
  • Publication number: 20120108531
    Abstract: Disclosed herein are novel phosphonate nucleosides and thiophosphonate nucleosides comprising a phosphonalkoxy-substituted or phosphonothioalkyl-substituted five-membered, saturated or unsaturated, oxygen-containing or sulfur-containing ring coupled to a heterocyclic nucleobase such as a pyrimidine or purine base. The invention further relates to compounds having HIV (Human Immunodeficiency Virus) replication inhibiting properties and to compounds having antiviral activities with respect to other viruses. The invention also relates to methods for preparation of all such compounds and pharmaceutical compositions comprising them. The invention further relates to the use of said compounds as a medicine and in the manufacture of a medicament useful for the treatment of subjects suffering from HIV infection, as well as for treatment of other viral, retroviral or lentiviral infections and to the treatment of animals suffering from FIV, viral, retroviral or lentiviral infections.
    Type: Application
    Filed: November 8, 2011
    Publication date: May 3, 2012
    Applicant: K.U.LEUVEN RESEARCH & DEVELOPMENT
    Inventors: Piet Herdewijn, Christophe Pannecouque, Tongfei Wu, Erik De clercq